| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED NOVEMBER 2020. Refer to TA667: Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | caplacizumab (Cablivi®) | |
| Formulation | 10 mg powder and solvent for solution for injection | |
| Reference number | 2953 | |
| Indication | Treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura, in conjunction with plasma exchange and immunosuppression |
|
| Company | Sanofi | |
| BNF chapter | Nutrition & blood | |
| Submission type | Non-submission | |
| Status | Superseded | |
| Date of issue | 05/03/2019 | |
| NICE guidance | ||